A Randomized, Double-blind, Parallel-group, Multi-center Study to Investigate the Pharmacodynamics and Pharmacokinetics of a Combined Oral Contraceptive Containing Levonorgestrel (LNG) and Ethinylestradiol (EE) When Given Together With Vilaprisan Over 3 Months in Healthy Women of Reproductive Age
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Dec 2018
At a glance
- Drugs Vilaprisan (Primary) ; Ethinylestradiol/levonorgestrel
- Indications Endometriosis; Uterine leiomyoma
- Focus Therapeutic Use
- Sponsors Bayer
- 12 Nov 2018 Planned End Date changed from 23 Nov 2018 to 21 Dec 2018.
- 10 Oct 2018 Planned End Date changed from 1 Nov 2018 to 23 Nov 2018.
- 10 Jul 2018 Planned End Date changed from 1 Oct 2018 to 1 Nov 2018.